Model created by Cedars-Sinai investigators could speed patient selection for clinical trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A group of investigators led by Cedars-Sinai have developed and successfully tested a new artificial intelligence method to make launching cancer clinical trials easier and faster. The method uses patients’ pathology reports to automate the classification of patients by the severity of their cancers, potentially shortening the process of selecting candidates for clinical trials.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Unfold AI, an AI prostate cancer mapping and clinical decision support platform, is now included in Medicare’s Physician Fee Schedules across the West Coast and Mountain West regions. The regional expansion of Medicare payment for the tool gives urologists and care teams clearer reimbursement pathways in physician office settings, an area that has historically lagged behind hospital outpatient settings for emerging technologies.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login